

16. Hardiman O, van den Berg LH. Edaravone: a new treatment for ALS on the horizon? *Lancet Neurol.* 2017;16:490-491.
17. Witzel S, Maier A, Steinbach R, et al. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. *JAMA Neurol.* 2022;79:121-130.
18. Gao M, Zhu L, Chang J, et al. Safety and Efficacy of Edaravone in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis. *Clin Drug Investig.* 2023;43:1-11.
19. Phase III study halted: Ferrer's oral edaravone disappoints in ALS – Pharmaceutical Technology. <https://www.pharmaceutical-technology.com/analyst-comment/phase-iii-study-halted-ferrer-oral-edaravone-disappoints-in-als/> (accessed 22 April 2024).
20. Van Damme P, Al-Chalabi A, Andersen PM, et al. European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD). *Eur J Neurol.* 2024;e16264.
21. Paganoni S, Hendrix S, Dickson SP, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. *Muscle Nerve.* 2021;63:31-39.
22. Morata-Tarifa C, Azkona G, Glass J, et al. Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis. *npj Regen Med.* 2021;6:1-10.
23. Norris FH, U KS, Sachais B, et al. Trial of baclofen in amyotrophic lateral sclerosis. *Arch Neurol.* 1979;36:715-716.
24. Su Zhang VR, Niu F, Lee EA, et al. Safety of baclofen versus tizanidine for older adults with musculoskeletal pain. *J Am Geriatr Soc.* 2023;71:2579-2584.
25. Meyer T, Funke A, Münch C, et al. Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD). *BMC Neurol.* 2019;19:222.
26. AminiLari M, Wang L, Neumark S, et al. Medical cannabis and cannabinoids for impaired sleep: a systematic review and meta-analysis of randomized clinical trials. *Sleep.* 2022;45:zsab234.
27. Vázquez-Costa JF, Máñez I, Alabajos A, et al. Safety and efficacy of botulinum toxin A for the treatment of spasticity in amyotrophic lateral sclerosis: results of a pilot study. *J Neurol.* 2016;263:1954-1960.
28. Garuti G, Rao F, Ribuffo V, et al. Sialorrhea in patients with ALS: current treatment options. *Degener Neurol Neuromuscul Dis.* 2019;9:19-26.
29. Slade A, Stanic S. Managing excessive saliva with salivary gland irradiation in patients with amyotrophic lateral sclerosis. *Journal of the Neurological Sciences.* 2015;352:34-36.
30. Garuti G, Rao F, Ribuffo V, et al. Sialorrhea in patients with ALS: current treatment options. *Degener Neurol Neuromuscul Dis.* 2019;9:19-26.
31. Miller TM, Layzer RB. Muscle cramps. *Muscle & Nerve.* 2005;32:431-442.
32. Garrison SR, Korownyk CS, Kolber MR, et al. Magnesium for skeletal muscle cramps. *Cochrane Database Syst Rev.* 2020;2020:CD009402.